Literature DB >> 21180448

Ophthalmic disorders in adult lymphoma patients.

Mohammad Javed Ali1, Santosh Honavar.   

Abstract

Entities:  

Year:  2010        PMID: 21180448      PMCID: PMC2991465          DOI: 10.4103/0974-9233.71582

Source DB:  PubMed          Journal:  Middle East Afr J Ophthalmol        ISSN: 0974-9233


× No keyword cloud information.
Sir, We read with great interest the article by Omoti et al.1 on the spectrum of ophthalmic disorders in adult patients with lymphoma. The article has systematically covered a wide variety of ophthalmic disorders. However, we do not completely agree with the authors’ contention that most reports of ocular involvement in lymphoma involve few patients. Cassoux et al.2 reported 42 cases and Hormigo et al.3 reported 31 cases of primary intraocular lymphoma in their respective study cohorts. Similarly, Shields et al.4 and Coupland et al.5 reported 117 and 37 cases, respectively, of conjunctival involvement in lymphoma. The authors have comprehensively documented the ocular and adnexal involvement in a series of patients with systemic lymphomas. It would also be of interest to the ophthalmologists to look at it from the other point of view. Shields et al.4 analyzed a large series of conjunctival lymphomas and found that 31% of them are associated with systemic lymphomas. Demirci and coworkers 67 in a large series of 160 patients noted that 25% had systemic association with orbital lymphomas, and more interestingly documented that 33% of orbital lymphomas at presentation subsequently developed systemic lymphomas over 10 years. Omoti et al.1 excluded all the patients on treatment in their analysis. It could have been possible to still elucidate ocular findings in at least some of these patients which would have further contributed to our understanding of lymphomas. The article also presents three cases of presumed lymphoma-associated retinopathy based only on features of hemorrhages and vasculitis. Although possible, we believe that angiocentric lymphomas are extremely rare and the classic presentation would be in the form of confluent, round, or geographic greasy-yellow subretinal pigment epithelium infiltrates. 8
  8 in total

1.  Conjunctival lymphoid tumors: clinical analysis of 117 cases and relationship to systemic lymphoma.

Authors:  C L Shields; J A Shields; C Carvalho; P Rundle; A F Smith
Journal:  Ophthalmology       Date:  2001-05       Impact factor: 12.079

2.  Orbital tumors in the older adult population.

Authors:  Hakan Demirci; Carol L Shields; Jerry A Shields; Santosh G Honavar; Gary J Mercado; Jose C Tovilla
Journal:  Ophthalmology       Date:  2002-02       Impact factor: 12.079

3.  Tumor detachments of the retinal pigment epithelium in ocular/ central nervous system lymphoma.

Authors:  J M Dean; M A Novak; C C Chan; W R Green
Journal:  Retina       Date:  1996       Impact factor: 4.256

4.  Ocular and central nervous system lymphoma: clinical features and diagnosis.

Authors:  N Cassoux; H Merle-Beral; V Leblond; B Bodaghi; D Miléa; S Gerber; C Fardeau; I Reux; K H Xuan; C C Chan; P LeHoang
Journal:  Ocul Immunol Inflamm       Date:  2000-12       Impact factor: 3.070

5.  Lymphoproliferative lesions of the ocular adnexa. Analysis of 112 cases.

Authors:  S E Coupland; L Krause; H J Delecluse; I Anagnostopoulos; H D Foss; M Hummel; N Bornfeld; W R Lee; H Stein
Journal:  Ophthalmology       Date:  1998-08       Impact factor: 12.079

6.  Ophthalmic disorders in adult lymphoma patients in Africa.

Authors:  Afekhide E Omoti; Caroline E Omoti; Rita O Momoh
Journal:  Middle East Afr J Ophthalmol       Date:  2009-10

7.  Orbital lymphoproliferative tumors: analysis of clinical features and systemic involvement in 160 cases.

Authors:  Hakan Demirci; Carol L Shields; Ekaterine C Karatza; Jerry A Shields
Journal:  Ophthalmology       Date:  2008-04-28       Impact factor: 12.079

8.  Ocular presentation of primary central nervous system lymphoma: diagnosis and treatment.

Authors:  Adília Hormigo; Lauren Abrey; Murk-Hein Heinemann; Lisa M DeAngelis
Journal:  Br J Haematol       Date:  2004-07       Impact factor: 6.998

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.